Binds Hormone, Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Glucagon, Cardiodilatin, Interleukin, Interferon, Norepinephrine, Epinephrine, Acetylcholine, Etc.) Patents (Class 530/389.2)
-
Publication number: 20130210038Abstract: The present invention relates to a method for diagnosing Q-fever in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of a Coxiella burnetii antigen and (c) determining the expression level of a pro-inflammatory cytokine such as IFN-? in said sample at the end of step (b).Type: ApplicationFiled: August 16, 2011Publication date: August 15, 2013Applicant: STICHTING KATHOLIEKE UNIVERSITEITInventors: Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Johannes Willem Maarten van der Meer, Bart Julian Kullberg, Marcel van Deuren
-
Publication number: 20130209489Abstract: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.Type: ApplicationFiled: August 15, 2011Publication date: August 15, 2013Inventors: Huiquan Han, Taruna Arora, Qing Chen, Hsieng Sen Lu, Xiaolan Zhou
-
Publication number: 20130202615Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: ApplicationFiled: June 14, 2011Publication date: August 8, 2013Applicant: VACCINEX, INC.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
-
Publication number: 20130203970Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: ApplicationFiled: August 20, 2012Publication date: August 8, 2013Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Publication number: 20130203963Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: ApplicationFiled: August 20, 2012Publication date: August 8, 2013Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Publication number: 20130195888Abstract: Disclosed herein are methods of purifying proteins using ultrafiltration and diafiltration processes.Type: ApplicationFiled: March 12, 2013Publication date: August 1, 2013Applicant: AbbVieInventors: Chen WANG, Germano COPPOLA, Johanna GERVAIS, Robert K. HICKMAN, Roy D. HEGEDUS, Gregory J. BUNK
-
Publication number: 20130197198Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: WYETH LLCInventor: WYETH LLC
-
Publication number: 20130195890Abstract: A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: AIMSCO LIMITEDInventor: AIMSCO LIMITED
-
Publication number: 20130189365Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.Type: ApplicationFiled: March 12, 2013Publication date: July 25, 2013Applicant: MANNKIND CORPORATIONInventor: MANNKIND CORPORATION
-
Publication number: 20130190225Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.Type: ApplicationFiled: November 5, 2012Publication date: July 25, 2013Inventors: Alexander M. DePaoli, Elif Ariogiu Oral, Simeon I. Taylor, Abhimanyu Garg
-
Patent number: 8487081Abstract: The present invention relates to antigen-binding proteins having specificity for hepcidin, and their use for treating and diagnosing diseases associated with hepcidin.Type: GrantFiled: October 2, 2008Date of Patent: July 16, 2013Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique-CNRSInventors: Sophie Vaulont, Hugues Gascan, Josy Froger
-
Publication number: 20130177572Abstract: The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR?) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.Type: ApplicationFiled: December 5, 2012Publication date: July 11, 2013Applicant: X-Body, Inc.Inventors: Yan CHEN, Richard W. Wagner, Csaba Pazmany
-
Publication number: 20130171096Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.Type: ApplicationFiled: October 24, 2012Publication date: July 4, 2013Applicant: AbbVie Inc.Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell
-
Publication number: 20130171165Abstract: The invention relates to methods of preparing antibody fragments. The invention further relates to antibody fragments prepared by these methods. The invention further relates to antibody variable regions comprised in antibody fragments producible by these methods.Type: ApplicationFiled: August 17, 2012Publication date: July 4, 2013Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias RAUM, Julia HENCKEL, Eva KRINNER, Silke MITTELSTRASS, Andreas WOLF
-
Publication number: 20130172535Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Inventor: Richard L. Gehant
-
Publication number: 20130171168Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: March 11, 2013Publication date: July 4, 2013Applicants: MEDAREX, INC., AMGEN INC.Inventors: Amgen Inc., Medarex, Inc.
-
Publication number: 20130171146Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1? and human IL-1?. The dual specific antibodies of the invention also neutralize both human IL-1? and human IL-1?. The invention also provides domain antibodies (dAbs) specific for human IL-1? and human IL-1?.Type: ApplicationFiled: August 21, 2012Publication date: July 4, 2013Applicant: ABBOTT LABORATORIESInventors: Chung-ming Hsieh, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Michael Roguska, Ian Tomlinson, Carrie Enever, Steven Grant, Mihriban Tuna
-
Publication number: 20130164304Abstract: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.Type: ApplicationFiled: December 7, 2012Publication date: June 27, 2013Applicant: ELI LILLY AND COMPANYInventor: Eli Lilly and Company
-
Publication number: 20130164302Abstract: The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner.Type: ApplicationFiled: December 14, 2012Publication date: June 27, 2013Applicant: Immuron LimitedInventor: Immuron Limited
-
Publication number: 20130164291Abstract: A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.Type: ApplicationFiled: December 21, 2012Publication date: June 27, 2013Applicant: CSL LimitedInventors: Brent MCKENZIE, Eugene MARASKOVSKY
-
Publication number: 20130164295Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: September 24, 2012Publication date: June 27, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventor: OncoMed Pharmaceuticals, Inc.
-
Publication number: 20130164256Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: October 24, 2012Publication date: June 27, 2013Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Tariq Ghayur, Lorenzo Benatuil, Yuliya Kutskova, John Memmott, Jennifer Perez, Suju Zhong, Carrie Goodreau, Anca Clabbers
-
Publication number: 20130156761Abstract: The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.Type: ApplicationFiled: February 25, 2013Publication date: June 20, 2013Applicants: Alliance Discovery, Inc., Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, Alliance Discovery, Inc.
-
Publication number: 20130149308Abstract: The present invention relates to compositions and methods for treatment of disease. More particularly, the present invention relates to anti-IL-1? and anti-IL-18 antibodies, including anti-IL-1? and anti-IL-18 bispecific antibodies, and methods of treating disease using such antibodies.Type: ApplicationFiled: February 11, 2013Publication date: June 13, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Patent number: 8461309Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.Type: GrantFiled: January 19, 2011Date of Patent: June 11, 2013Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Christof Niehrs, Andrei Glinka
-
Publication number: 20130142799Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: November 19, 2012Publication date: June 6, 2013Applicant: AMGEN, INC.Inventor: Amgen, Inc.
-
Publication number: 20130143813Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.Type: ApplicationFiled: December 7, 2011Publication date: June 6, 2013Applicant: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
-
Publication number: 20130131322Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.Type: ApplicationFiled: May 17, 2011Publication date: May 23, 2013Applicant: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
-
Publication number: 20130122018Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: January 10, 2013Publication date: May 16, 2013Applicant: ABBOTT BIOTECH LTD (BERMUDA)Inventor: Abbott Biotech Ltd (Bermuda)
-
Publication number: 20130115224Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: January 8, 2013Publication date: May 9, 2013Inventors: Jochen G. SALFELD, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.j.m. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20130116135Abstract: The present inventors have identified a panel of biomarkers present in a biological sample of an individual (e.g. blood, including serum or plasma) whose concentrations or levels are altered in individuals with a neurological disorder. Accordingly, changes in the level of any one or more of these biomarkers can be used to assess cognitive function, to diagnose or aid in the diagnosis of a neurological disorder and/or to monitor a neurological disorder in a patient (e.g., tracking disease progression in a patient and/or tracking the effect of medical or surgical therapy in the patient). Changes in the level of any one or more of these biomarkers can also be used to stratify a patient (i.e., sorting an individual with a probable diagnosis of a neurological disorder or diagnosed with a neurological disorder into different classes of the disorder) and diagnosing or aiding in the diagnosis of mild cognitive impairment (MCI) as well as diagnosing or aiding in the diagnosis of cognitive impairment.Type: ApplicationFiled: November 24, 2010Publication date: May 9, 2013Applicant: Commonweath Scientific and Industrial Research OrganisationInventors: James Doecke, Holly Soares, Simon Matthew Laws, Noel Garry Faux
-
Publication number: 20130115166Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: ApplicationFiled: July 20, 2011Publication date: May 9, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Patent number: 8435525Abstract: The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.Type: GrantFiled: November 7, 2010Date of Patent: May 7, 2013Inventor: Andrew B. Bush
-
Publication number: 20130108644Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.Type: ApplicationFiled: August 27, 2012Publication date: May 2, 2013Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
-
Publication number: 20130101601Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.Type: ApplicationFiled: October 24, 2012Publication date: April 25, 2013Applicant: ANAPTYSBIO, INC.Inventor: AnaptysBio, Inc.
-
Publication number: 20130101595Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: September 5, 2012Publication date: April 25, 2013Applicant: Abbott LaboratoriesInventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Publication number: 20130101602Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.Type: ApplicationFiled: December 19, 2012Publication date: April 25, 2013Applicant: ARGOS THERAPEUTICS, INC.Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
-
Patent number: 8415459Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: October 31, 2008Date of Patent: April 9, 2013Assignee: Pfizer Inc.Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman
-
Patent number: 8415460Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: June 12, 2009Date of Patent: April 9, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Karin Franz-Bacon, Daniel M. Gorman, Terrill K. McClanahan
-
Patent number: 8409579Abstract: The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same.Type: GrantFiled: June 29, 2012Date of Patent: April 2, 2013Assignee: Genentech, Inc.Inventors: Mark Dennis, Luc Desnoyers, Dorothy French
-
Publication number: 20130078237Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Inventors: John M. DELANEY, William Christian FANSLOW, III, Chadwick Terence KING
-
Publication number: 20130071401Abstract: A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (IAPP). Antibodies recognizing same are also disclosed. Use of the composition of matter and the antibodies are also disclosed.Type: ApplicationFiled: June 2, 2011Publication date: March 21, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Yaron Bram, Ehud Gazit
-
Publication number: 20130071431Abstract: The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: Stabilitech Ltd.Inventor: Stabilitech Ltd.
-
Patent number: 8398995Abstract: A method for inducing immune tolerance to type I diabetes in a mammal by mucosal delivery of an antigen involved in the induction of type I diabetes such as pro-insulin or insulin is disclosed. The antigen involved in the induction of type I diabetes is delivered together with an IL-10 secreting micro-organism such as Lactococcus lactis and a anti-CD3 antibody.Type: GrantFiled: October 9, 2009Date of Patent: March 19, 2013Assignee: Actogenix NVInventors: Pieter Rottiers, Veerle Snoeck
-
Patent number: 8398966Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: GrantFiled: October 15, 2010Date of Patent: March 19, 2013Assignee: AbbVie Inc.Inventors: Chengbin Wu, Chung-ming Hsieh, Renee Miller, Dominic J. Ambrosi
-
Patent number: 8394930Abstract: An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof.Type: GrantFiled: April 27, 2010Date of Patent: March 12, 2013Assignee: University of BristolInventors: David O. Bates, Steven J. Harper
-
Publication number: 20130058943Abstract: The invention provides a composition comprising polyclonal antibodies that specifically bind to with human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized hTNF or an immunogenic portion thereof. The antigenic specificity analysis of the anti-hTNF polyclonal antibodies of the invention is unique and has not been previously described for anti-hTNF polyclonal or monoclonal antibodies of the prior art.Type: ApplicationFiled: August 1, 2012Publication date: March 7, 2013Inventors: Barbara S. Fox, Eileen F. Bostwick, Daniel E. Tracey, Lisa D. Schlehuber, Michael S. Quesenberry
-
Publication number: 20130058927Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: October 31, 2012Publication date: March 7, 2013Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Patent number: 8388956Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: September 2, 2011Date of Patent: March 5, 2013Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 8388969Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: September 2, 2011Date of Patent: March 5, 2013Assignee: Xbiotech, Inc.Inventor: John Simard